Doctors in Delhi successfully treated liver cancer in a 72-year-old high-risk patient without surgery using a minimally ...

Balt’s Squid liquid embolic receives US FDA approval for adjunctive treatment for chronic subdural hematomas: Boston Friday, February 6, 2026, 17:00 Hrs [IST] Balt Inc, a global ...

As open surgery posed a life-threatening risk, doctors opted for Transarterial Chemoembolization (TACE)—a minimally invasive, ...

Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is approved for the embolization of the middle ...

For many women, uterine fibroids are an unseen battle, onethat quietly reshapes daily life through heavy menstrual bleeding, pelvicpressure, fatigue, and emotional distress. Though fibroids are benign ...

Boston Scientific Corporation (NYSE:BSX) Q4 2025 Earnings Call Transcript February 4, 2026 Boston Scientific Corporation beats earnings expectations. Reported EPS is $0.8, expectations were $0.78.

Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid liquid embolic agent. Squid is approved ...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and ...

Southeast Asia Medical Wearable Devices Market was valued at ~USD 2,080.65 million in 2024 grow at a strong CAGR of ...

In 2025, the ambulatory surgery center (ASC) market continued to solidify its role as a core site of care for elective and ...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025 ...